ArticleACR open rheumatology2026
Longitudinal Assessment of the Juvenile Systemic Sclerosis Severity Score: Application in the National Registry for Childhood Onset Scleroderma.
Article in ACR open rheumatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
objectiveJuvenile-onset systemic sclerosis (jSSc) is a rare, heterogeneous pediatric autoimmune disease. Existing severity tools are often adapted from adult systemic sclerosis and lack pediatric-specific validation. The Juvenile Systemic Sclerosis Severity Score (J4S) was developed to address this gap by capturing multiorgan disease burden. This study evaluated the clinical use of the J4S using data from the National Registry for Childhood Onset Scleroderma (NRCOS).
methodsWe applied the J4S to 58 patients in the NRCOS cohort, analyzing scores at baseline and at one-, two-, and three-year follow-ups. Subdomain scores were assessed to evaluate organ-specific trends. An exploratory version with equal domain weighting was also tested for sensitivity.
resultsAt baseline, the mean J4S was 8.18 (±3.64), with respiratory involvement as the primary contributor. Although no significant change in total scores was observed at one (P = 0.264) or two years (P = 0.06), domain-specific improvements were noted, particularly in the skin, vascular, gastrointestinal, and musculoskeletal systems. By three years, total scores declined significantly (P = 0.028). Two patients experienced sharp score increases due to respiratory decline; one patient died during the study. The exploratory equal-weight scoring approach improved sensitivity to change and identified significant declines at each time point.
conclusionThe J4S is a valuable longitudinal tool for tracking disease severity and organ involvement in jSSc. It can identify both stable and progressive disease and may help detect patients at risk for poor outcomes. Modifying domain weighting may enhance responsiveness. Future multicenter validation and clinical trial integration are warranted.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.